NetworkNewsBreaks – Mydecine Innovations Group I
Post# of 160
(Total Views: 209)
Posted On: 11/17/2021 3:33:35 PM
NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Featured in ROTH Equity Research Report
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are reiterating our Buy rating and C$3/share 12-month price target on Mydecine following the release of 3Q21 results. . . The highlight of the quarter was the announcement that Mydecine plans to continue clinical research that was initiated a number of years ago at Johns Hopkins University, under the leadership of Dr. Matthew Johnson, a world-renowned psychedelic drug researcher. In a small, preliminary, open-label pilot study (n=15), it was shown that 80% of the subjects achieved abstinence at six months following a 2-3 oral doses of psilocybin coupled with extensive cognitive behavioral therapy (‘CBT’). In a recent update, Dr. Johnson disclosed preliminary data from an ongoing 80-subject randomized trial. Fifty-nine percent of those treated with psilocybin and CBT were abstinent at 12 months vs. 27% with CBT treatment alone.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are reiterating our Buy rating and C$3/share 12-month price target on Mydecine following the release of 3Q21 results. . . The highlight of the quarter was the announcement that Mydecine plans to continue clinical research that was initiated a number of years ago at Johns Hopkins University, under the leadership of Dr. Matthew Johnson, a world-renowned psychedelic drug researcher. In a small, preliminary, open-label pilot study (n=15), it was shown that 80% of the subjects achieved abstinence at six months following a 2-3 oral doses of psilocybin coupled with extensive cognitive behavioral therapy (‘CBT’). In a recent update, Dr. Johnson disclosed preliminary data from an ongoing 80-subject randomized trial. Fifty-nine percent of those treated with psilocybin and CBT were abstinent at 12 months vs. 27% with CBT treatment alone.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Mydecine Innovations Group Inc (MYCOF) Stock Research Links
Scroll down for more posts ▼